CDKN1A and acute myeloid leukemia: These effects are exerted by multiple complementary mechanisms involving the modulation of p21 protein levels, inactivation of the PI3K/AKT pathway, and activation of the p53/p21 pathway 36,37, leading to synergistic anti-leukemic activity against FLT3-ITD AML.